Literature DB >> 20127100

Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases.

Alfred Balasa1, Grace Gathungu, Peter Kisfali, E O'Brian Smith, Judy H Cho, Bela Melegh, Richard Kellermayer.   

Abstract

BACKGROUND AND AIMS: A 5-bp insertion-deletion (indel) polymorphism in the promoter of interferon regulatory factor 5 (IRF5) has been associated with inflammatory bowel diseases (IBD). This polymorphism generates an additional binding site for the transcription factor SP1 and has been shown to augment the expression of IRF5. Additionally, it affects a CpG dinucleotide-dense genomic region. These features of the indel suggested that it may influence the epigenetic regulation of IRF5. The aim of this study was to investigate the potential effect of the 5-bp indel on the methylation pattern of four CpG sites upstream of the polymorphism. Possible CpG site methylation differences in this region between healthy persons and individuals suffering from IBD were also tested.
METHODS: Genotype was determined by 4% polyacrylamide gel electrophoresis in 33 peripheral blood leukocyte (PBL) DNA samples. DNA methylation correlates of the genotypes were measured by bisulfite pyrosequencing. IRF5 promoter methylation in association to disease state was assessed in 87 proband (49 healthy, 18 Crohn's disease, 20 ulcerative colitis) PBL samples.
RESULTS: The polymorphism did not affect the methylation pattern of the IRF5 promoter nor could we detect significant differences in the average, low methylation of the locus between healthy persons and individuals with IBD.
CONCLUSIONS: These results implicate that epigenetic dysregulation of the IRF5 promoter is unlikely to be associated with IBD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127100      PMCID: PMC5751749          DOI: 10.1007/s00384-010-0874-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  23 in total

Review 1.  DNA methylation and human disease.

Authors:  Keith D Robertson
Journal:  Nat Rev Genet       Date:  2005-08       Impact factor: 53.242

2.  Epigenetics and twins: three variations on the theme.

Authors:  Arturas Petronis
Journal:  Trends Genet       Date:  2006-05-11       Impact factor: 11.639

3.  Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis.

Authors:  Lanlan Shen; Yi Guo; Xinli Chen; Saira Ahmed; Jean-Pierre J Issa
Journal:  Biotechniques       Date:  2007-01       Impact factor: 1.993

4.  Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation.

Authors:  Kristi Kerkel; Alexandra Spadola; Eric Yuan; Jolanta Kosek; Le Jiang; Eldad Hod; Kerry Li; Vundavalli V Murty; Nicole Schupf; Eric Vilain; Mitzi Morris; Fatemeh Haghighi; Benjamin Tycko
Journal:  Nat Genet       Date:  2008-06-22       Impact factor: 38.330

5.  Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC).

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Masakatsu Nakamura; Hiromi Yamashita; Daisuke Yoshioka; Masaaki Okubo; Naoko Maruyama; Toshiaki Kamano; Yoshio Kamiya; Hiroshi Fujita; Yoshihito Nakagawa; Mitsuo Nagasaka; Masami Iwata; Kazuya Takahama; Makoto Watanabe; Hiroshi Nakano; Ichiro Hirata; Tomiyasu Arisawa
Journal:  Clin Exp Med       Date:  2009-01-30       Impact factor: 3.984

6.  Sp1 elements protect a CpG island from de novo methylation.

Authors:  M Brandeis; D Frank; I Keshet; Z Siegfried; M Mendelsohn; A Nemes; V Temper; A Razin; H Cedar
Journal:  Nature       Date:  1994-09-29       Impact factor: 49.962

7.  Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.

Authors:  Thomas Mikeska; Christoph Bock; Osman El-Maarri; Anika Hübner; Denise Ehrentraut; Johannes Schramm; Jörg Felsberg; Philip Kahl; Reinhard Büttner; Torsten Pietsch; Andreas Waha
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

8.  Genetic and epigenetic mechanisms combine to control MMP1 expression and its association with preterm premature rupture of membranes.

Authors:  Hongyan Wang; Masaki Ogawa; Jennifer R Wood; Marisa S Bartolomei; Mary D Sammel; Juan Pedro Kusanovic; Scott W Walsh; Roberto Romero; Jerome F Strauss
Journal:  Hum Mol Genet       Date:  2008-01-04       Impact factor: 6.150

9.  Crohn's disease.

Authors:  Malathi Sathiyasekaran; So Shivbalan
Journal:  Indian J Pediatr       Date:  2006-08       Impact factor: 5.319

10.  Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping.

Authors:  Christoph Bock; Jörn Walter; Martina Paulsen; Thomas Lengauer
Journal:  Nucleic Acids Res       Date:  2008-04-15       Impact factor: 16.971

View more
  8 in total

1.  IRF5 guides monocytes toward an inflammatory CD11c+ macrophage phenotype and promotes intestinal inflammation.

Authors:  Alastair L Corbin; Maria Gomez-Vazquez; Dorothée L Berthold; Moustafa Attar; Isabelle C Arnold; Fiona M Powrie; Stephen N Sansom; Irina A Udalova
Journal:  Sci Immunol       Date:  2020-05-22

2.  Colonic mucosal DNA methylation, immune response, and microbiome patterns in Toll-like receptor 2-knockout mice.

Authors:  Richard Kellermayer; Scot E Dowd; R Alan Harris; Alfred Balasa; Tiffany D Schaible; Randy D Wolcott; Nina Tatevian; Reka Szigeti; Zhijie Li; James Versalovic; C Wayne Smith
Journal:  FASEB J       Date:  2011-01-12       Impact factor: 5.191

3.  Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases.

Authors:  R Alan Harris; Dorottya Nagy-Szakal; Natalia Pedersen; Antone Opekun; Jiri Bronsky; Pia Munkholm; Cathrine Jespersgaard; PaalSkytt Andersen; Bela Melegh; George Ferry; Tine Jess; Richard Kellermayer
Journal:  Inflamm Bowel Dis       Date:  2012-03-29       Impact factor: 5.325

4.  A functional methylome map of ulcerative colitis.

Authors:  Robert Häsler; Zhe Feng; Liselotte Bäckdahl; Martina E Spehlmann; Andre Franke; Andrew Teschendorff; Vardhman K Rakyan; Thomas A Down; Gareth A Wilson; Andrew Feber; Stephan Beck; Stefan Schreiber; Philip Rosenstiel
Journal:  Genome Res       Date:  2012-07-23       Impact factor: 9.043

Review 5.  Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.

Authors:  Karen Dubois-Camacho; Payton A Ottum; Daniel Franco-Muñoz; Marjorie De la Fuente; Alejandro Torres-Riquelme; David Díaz-Jiménez; Mauricio Olivares-Morales; Gonzalo Astudillo; Rodrigo Quera; Marcela A Hermoso
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 6.  New Insights Into the Epigenetic Regulation of Inflammatory Bowel Disease.

Authors:  Jing Xu; Hao-Ming Xu; Mei-Feng Yang; Yu-Jie Liang; Quan-Zhou Peng; Yuan Zhang; Cheng-Mei Tian; Li-Sheng Wang; Jun Yao; Yu-Qiang Nie; De-Feng Li
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

Review 7.  DNA methylation changes in inflammatory bowel disease.

Authors:  Pantelis S Karatzas; Maria Gazouli; Michael Safioleas; Gerasimos J Mantzaris
Journal:  Ann Gastroenterol       Date:  2014

8.  Euphorbia Factor L2 ameliorates the Progression of K/BxN Serum-Induced Arthritis by Blocking TLR7 Mediated IRAK4/IKKβ/IRF5 and NF-kB Signaling Pathways.

Authors:  Jing Tang; Xiaolan Cheng; Shiyu Yi; Yuanyuan Zhang; Zhigang Tang; Yutong Zhong; Qiuping Zhang; Bin Pan; Yubin Luo
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.